NorthStrive Biosciences Files New U.S. Patent Application for EL-22 Targeting Muscle Preservation in Humans
Rhea-AI Summary
NorthStrive Biosciences (Nasdaq: ELAB) filed U.S. Patent Application No. 19/655,160 to expand its EL-22 myostatin-engineered probiotic into human pharmaceutical uses.
The application covers formulated pharmaceutical products, specific dosing regimens and formulations for a broad range of muscle-wasting conditions including sarcopenia, disuse atrophy and certain neurological disorders, and notes potential use alongside GLP-1 weight-loss treatments. The filing aims to strengthen NorthStrive's intellectual property portfolio for muscle-preservation therapeutics.
Positive
- Filed U.S. patent application No. 19/655,160 for EL-22 human pharmaceutical use
- Patent claims include specific dosing regimens and formulations for muscle-wasting conditions
- Targets multiple indications including sarcopenia, disuse atrophy, and certain neurological disorders
- Notes potential application of EL-22 alongside GLP-1 weight-loss treatments
Negative
- Patent application status is pending; no issued patent rights yet
- No clinical trial data, regulatory approvals, or timelines provided in the filing
- No financial impact, commercialization timeline, or revenue guidance disclosed
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 23 | Defense tech option | Positive | -5.5% | Exclusive option on GPS-denied autonomous drone navigation patent rights. |
| Apr 21 | Supply agreement | Positive | -0.9% | SVM Machining long-term deal to supply aerospace and defense components. |
| Apr 17 | Equity facility | Negative | -13.9% | Announcement of a $40 million equity purchase facility using pre-paid structure. |
| Apr 13 | Biotech manufacturing | Positive | +6.0% | Transfer of EL-32 working cell bank and start of manufacturing optimization. |
| Apr 10 | Trade show presence | Positive | -8.9% | Pacific Sun Packaging exhibiting at ITAD Europe 2026 for global expansion. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent ELAB news often saw negative or mixed price reactions, even on operationally positive updates, with only select biotech-focused announcements trading in alignment.
Over recent weeks, ELAB reported multiple developments across defense, manufacturing, and biosciences. On April 13, a NorthStrive EL-32 manufacturing update drew a 6.05% gain, one of the few positive alignments. In contrast, financing news on April 17 tied to a $40 million equity facility coincided with a -13.91% move. Several aerospace and packaging headlines saw share price declines. Today’s patent filing for EL-22 extends the muscle-health biotech narrative within this diversified platform.
Key Terms
myostatin medical
probiotic medical
glp-1 receptor agonists medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWPORT BEACH, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (“NorthStrive” or the “Company”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC”), today announced the filing of a new U.S. patent application expanding its proprietary EL-22, a myostatin-engineered probiotic technology, into human pharmaceutical applications.
The patent application (U.S. Application No. 19/655,160) covers the development of a formulated pharmaceutical product utilizing EL-22 for use in human patients suffering from muscle loss. The application includes protection for specific dosing regimens and formulations targeting a broad range of muscle-wasting conditions.
The proposed therapeutic use of EL-22 is intended to address muscle loss associated with conditions such as sarcopenia, muscle disuse atrophy, and certain neurological disorders. This filing expands NorthStrive’s intellectual property strategy, building on prior applications focused on muscle preservation and growth.
NorthStrive’s lead asset, EL-22, leverages a myostatin engineered probiotic approach designed to support muscle preservation and growth, including in patients undergoing weight loss treatments such as GLP-1 receptor agonists.
This newly filed patent application is intended to strengthen NorthStrive’s expanding intellectual property portfolio and reflects the Company’s focus on muscle health therapeutics across pharmaceutical and adjacent markets.
About NorthStrive Biosciences Inc.
NorthStrive Biosciences Inc., a PMGC Holdings Inc. company, is a biopharmaceutical company focused on the development and acquisition of cutting-edge therapeutic technologies. The Company is advancing a pipeline of assets targeting muscle preservation, metabolic health, and related conditions.
About PMGC Holdings Inc.
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across multiple industries. PMGC is focused on building long-term shareholder value through operational excellence and disciplined capital allocation. For more information, please visit https://www.pmgcholdings.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although PMGC believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and PMGC cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of PMGC’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, PMGC undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact:
